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SUMMARY
The role of ERb in prostate cancer is unclear,
although loss of ERb is associated with aggressive
disease. Given that mice deficient in ERb do not
develop prostate cancer, we hypothesized that ERb
loss occurs as a consequence of tumorigenesis
caused by other oncogenic mechanisms and that
its loss is necessary for tumorigenesis. In support
of this hypothesis, we found that ERb is targeted
for repression in prostate cancer caused by PTEN
deletion and that loss of ERb is important for tumor
formation. ERb transcription is repressed by BMI-1,
which is induced by PTEN deletion and important
for prostate tumorigenesis. This finding provides a
mechanism for how ERb expression is regulated
in prostate cancer. Repression of ERb contributes
to tumorigenesis because it enables HIF-1/VEGF
signaling that sustains BMI-1 expression. These
data reveal a positive feedback loop that is activated
in response to PTEN loss and sustains BMI-1.
INTRODUCTION
The role of estrogen receptors (ERs) in epithelial cell biology and
cancer is an emerging area of considerable biological interest
and pathological relevance. In the prostate, ERb is expressed
in epithelial cells, while ERa expression is confined to stromal
cells (Kuiper et al., 1996; Leav et al., 2001; Thomas and Gustafs-
son, 2011). The contribution of ERb to prostate cancer appears
to be significant, but much remains to be learned (Christoforou
et al., 2014; Dey et al., 2013). The inverse correlation between
the expression of ERb and differentiation (Gleason score) (Leav
et al., 2001; Mak et al., 2010) is supported by mechanistic cell
biology studies demonstrating that one function of ERb is to
impede an epithelial mesenchymal transition (EMT) (Mak et al.,
2010, 2013). The mechanism involves the ability of ERb to sus-
tain prolyl hydroxylase 2 (PHD2) expression and subsequently
promote HIF-1a degradation and HIF-1-mediated EMT (Mak
et al., 2013).
An important and timely issue is the contribution of ERb to
prostate tumorigenesis. Although the loss of ERb is associated
with a higher Gleason grade and more aggressive disease, a
causal role for ERb in impeding the formation of aggressive tu-
mors has not been established. There is evidence that loss of
ERb can increase the incidence of poorly differentiated prostate
carcinoma, but the mechanism is not known (Slusarz et al.,
2012). This problem has been obscured by the analysis of
ERb knockout (BERKO) mice. These mice do not develop pros-
tate cancer (Antal et al., 2008; Imamov et al., 2004), although
some studies have observed prostate hyperplasia in older
BERKO mice (Imamov et al., 2004). Furthermore, deletion of
ERb in the FGF8b transgenic model of prostate tumorigenesis
did not increase tumor incidence, a finding that has been
used to discount a tumor-suppressive function for ERb (Elo
et al., 2014).
We approached the problem of the potential role of ERb
in prostate tumorigenesis from a different perspective. Specif-
ically, we hypothesized that ERb loss occurs as a conse-
quence of tumorigenesis caused by other oncogenic mecha-
nisms and that its loss is necessary for this tumorigenesis.
To test this hypothesis, we focused on prostate tumorigenesis
induced by PTEN loss for several reasons. Inactivation or
loss of PTEN is one of the most common genetic lesions in
prostate cancer, and its frequency increases with Gleason
grade and more aggressive disease (Cairns et al., 1997; Goel
et al., 2012; McMenamin et al., 1999). Given that ERb loss
also increases with de-differentiated, aggressive disease
(Mak et al., 2010), these observations suggest a causal rela-
tionship between loss of PTEN and loss of ERb that may
be significant for prostate tumorigenesis. The results pre-
sented in this study validate this hypothesis and provide a
mechanism for how PTEN loss results in the transcriptional
repression of ERb that involves BMI-1, an oncogene that reg-
ulates cell proliferation and senescence through the ink4a lo-
cus (Jacobs et al., 1999) and has been implicated in prostate
tumorigenesis (Lukacs et al., 2010). Importantly, we also
establish that the loss of ERb is necessary for tumorigenesis
caused by PTEN loss because it enables autocrine VEGF
signaling, which has been implicated in the genesis of several
cancers including prostate (reviewed in Goel and Mercurio
[2013]).
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RESULTS
ERb Is Targeted for Repression in Prostate
Tumorigenesis Induced by PTEN Loss
To assess the potential relationship between ERb and PTEN, we
evaluated ERb expression in a transgenic model of prostate
tumorigenesis mice induced by PTEN deletion (Ptenloxp/loxp;
PB-Cre+ [referred to as Pten pc/]). Prostate-specific deletion
of PTEN results in tumors that are invasive and aggressive
(Wang et al., 2003). The normal glandular features of the wild-
type prostates (control) and tumor formation in age-matched
Pten pc/ prostates are shown in Figure 1A. PTEN expression
is apparent in wild-type prostates but absent in Pten pc/
mice (Figure 1B). Importantly, ERb expression is lost in Pten
pc/ mice, whereas the age-matched wild-type prostates
exhibit ERb expression (Figure 1C). We also observed that
PTEN and ERb expression correlate in human prostate tumors
based on analysis of the cBioportal database (Figure 1D;
Table S1). High Gleason grade tumors (primary Gleason grade 5)
exhibit uniform loss of PTEN and ERb (Cairns et al., 1997; Mak
et al., 2010). Gleason grade 3 tumors are interesting in this regard
because these tumors are characterized by heterogeneity in
PTEN expression (McMenamin et al., 1999). Indeed, we quanti-
fied PTEN and ERb mRNA expression in grade 3 tumors and
observed a correlation between PTEN and ERb expression
(Figure 1E).
To investigate the relationship between ERb and PTEN further,
we depleted PTEN in PNT1a cells, an immortalized prostate
epithelial cell line (Berthon et al., 1995). Depletion of PTEN
caused an EMT consistent with previous reports (Mulholland
et al., 2012; Song et al., 2009), and it also resulted in a decrease
in ERbmRNA and protein expression compared to control cells,
indicating that PTEN regulates ERb expression (Figure 1F). In
contrast, ERb does not appear to impact PTEN expression
because depletion of ERb did not alter PTEN levels (Figure 1G).
Furthermore, two physiological ligands of ERb (3b-Adiol and
17b-estradiol:E2) did not affect PTEN expression (Figure 1G).
Interestingly, both a PI3K inhibitor (wortmannin) and Akt inhibitor
(Akt Inhibitor VIII) reversed the mesenchymal phenotypes of
PTEN-depleted PNT1a cells to an epithelial phenotype with a
concomitant restoration of ERb expression (Figure 1H).
To support a functional link between PTEN and ERb expres-
sion, we examined the effect of expressing ERb in PTEN-
depleted PNT1a cells. The mesenchymal morphology of
PTEN-depleted cells reverted to an epithelial morphology in
response to expression of HA-ERbwith a concomitant decrease
in mesenchymal markers (N-cadherin and vimentin) (Figure 2A).
We also assessed the tumor-suppressive activity of ERb in the
context of PTEN by injecting control cells, PTEN-depleted cells,
and PTEN-depleted cells that express ERb into nude mice. Con-
trol cells did not form tumors after 9 weeks, whereas 71% of
mice injected with PTEN-depleted cells had tumors at this time
(Figure 2B). More importantly, tumor formation was greatly
reduced (12% of mice had tumors) when mice were injected
with PTEN-depleted cells expressing HA-ERb (Figure 2B). This
observation was substantiated by expressing ERb in PC3-M
cells, a highly tumorigenic, PTEN-prostate cancer cell line (Ko-
zlowski et al., 1984) that expresses low levels of ERb (Figure 2C).
Indeed, ERb expression dramatically reduced the ability of these
cells to form tumors (Figure 2C).
BMI-1 Is a Transcriptional Repressor of ERb
To define the mechanism by which loss of PTEN diminishes ERb
expression, we focused on BMI-1, the key regulatory component
of the polycomb repressive complex-1 that modulates chro-
matin structure and represses the transcription of a number of
genes (Cao et al., 2005; Jacobs et al., 1999; Miyazaki et al.,
2008), for several reasons. BMI-1 has been implicated in pros-
tate hyperplasia and tumorigenesis (Lukacs et al., 2010; van
Leenders et al., 2007). We also found that expression of BMI-1
in ERb-expressing PTEN-depleted cells promoted tumor forma-
tion (Figure 2C). Furthermore, PTEN loss induces BMI-1 expres-
sion (Goel et al., 2012), as evident in PNT1a cells (Figure 2D). The
ability of both wortmannin and Akt Inhibitor VIII to attenuate
BMI-1 expression in shPTEN cells supports our previous finding
on their ability to restore ERb expression in these cells (Fig-
ure 2E). For these reasons, we evaluated the possibility that
BMI-1 represses ERb. Expression of BMI-1 in PNT1a cells sup-
pressed ERb compared to control cells (Figure 2F). Conversely,
we depleted BMI-1 in PC3-M cells and observed an induction of
ERb expression compared to the control (Figure 2G). We also
observed that 17b-estradiol (E2) had no effect on the expression
of BMI-1 on PTEN-depleted cells, suggesting that ERa does not
regulate BMI-1 (Figure 2H). The multiple bands observed in the
BMI-1 immunoblots may represent phosphorylated forms of
the protein (Nacerddine et al., 2012).
The inverse functional relationship between BMI-1 and ERb
prompted us to test the possibility that BMI-1 is a transcriptional
repressor of ERb. Therefore, we performed chromatin immuno-
precipitation (ChIP) analysis on the ERb promoter to assess
BMI-1 binding. We examined eight regions within the 3 kb span-
ning from +331 to 2,996 base pairs and detected one major
BMI-1 binding locus in region 1 proximal to the transcription start
site (Figure 2I; Figure S1A). The impact of BMI-1 on ERb pro-
moter activity was evaluated by expressing luciferase reporter
constructs containing two regions of the promoter (region 1
and regions 1 and 2) in control and BMI-1-depleted PC3-M cells.
Diminishing BMI-1 expression resulted in a significant increase in
luciferase activity in both constructs compared to the control
(Figure 2J). Moreover, this activity was concentrated in region
1, supporting our ChIP data. Given that ERb expression is regu-
lated by two promoters, 0N and 0K (Hirata et al., 2001), we
sought to determine which promoter is utilized by BMI-1 to exert
its repressive function. The BMI-1 binding locus of region 1 in our
ChIP assays lined up perfectly within the 0N promoter, but not
within the 0K promoter (Figure S1B). These data indicate that
ERb transcription is repressed by BMI-1 on the 0N promoter.
Role of ERb Repression in Prostate Tumorigenesis
The critical issue that arises from the foregoing observations is
why ERb repression is important for prostate tumorigenesis
induced by PTEN loss (see Figure 1A). Previously, we reported
that loss of ERb stabilizes HIF-1a and enables autocrine VEGF
signaling in prostate cancer cells (Mak et al., 2010). This finding
is relevant because autocrine VEGF signaling has emerged as an
important component of tumorigenesis (Goel and Mercurio,
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Figure 1. ERb Is Targeted for Repression in Prostate Tumorigenesis Induced by PTEN Loss
(A) H&E staining of ventral prostates of wild-type (control) and aged-matched Pten pc/mice is shown.
(B and C) The expression of PTEN (B) and ERb (C) in these tissues was examined by immunofluorescence microscopy. Scale bar, 50 mm.
(D) A positive correlation between PTEN and ERb expression in a cohort of 34 prostate tumors was determined from the cBioportal database.
(E) Four different Grade 3 tumors were analyzed by qPCR for ERb and PTEN mRNA expression.
(F) PTEN-depleted PNT1a cells (shPTEN-1 and shPTEN-2) and control (shGFP) PNT1a cells were analyzed for morphology (phase contrast images) and
expression of ERb and PTEN (immunoblot). PTEN mRNA expression was also quantified by qPCR (bar graph).
(G) Immunoblot shows PTEN expression in ERb-depleted (shERb-1 and shERb-2) and control (shGFP) PNT1a cells. Bar graph depicts the lack of an effect of
3b-Adiol and estrogen (E2) treatment on PTEN mRNA expression. Data represent the average of three experiments (±SEM).
(H) Effects of wortmannin and Akt Inhibitor VIII on cell morphology and ERb expression in shPTEN PNT1a cells are shown. See also Table S1.
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Figure 2. ERb Impedes Tumor Initiation Induced by PTEN Loss
(A) HA-ERb was expressed in PTEN-depleted cells and the impact on cell morphology (phase contrast images) and expression of ERb (immunoblot) was
evaluated. Scale bar, 50 mm.
(B) The indicated cells (105) were injected subcutaneously into nu/nu mice (n = 7) and tumor formation was assessed by palpation. The curve comparison was
done using log rank test (p < 0.05).
(C) HA-ERbwas expressed in PC3-M cells, which are PTEN and express a very low level of ERb. The indicated cells (105) were injected subcutaneously into nu/
nu mice (n = 7) and tumor formation was assessed by palpation. The curve comparison was done using log rank test (p < 0.05).
(D) Effects of wortmannin and Akt Inhibitor VIII on BMI-1 expression in shPTEN PNT1a cells are shown.
(E) Expression of BMI-1 in PTEN-depleted (shPTEN) and control (shGFP) PNT1a cells is shown.
(F) BMI-1 was expressed in PNT1a cells and the effect on ERb expression was evaluated by immunoblotting.
(G) BMI-1 expression was diminished in PC3-M cells using shRNAs (shBMI-1 and shBMI-2) and the expression of ERb was assessed (immunoblots).
(H) Effect of estrogen (E2, 10 nM) on BMI-1 expression in shPTEN cells is shown.
(I) Schematic of the ERb promoter shows the primer sets that were used to assess binding activity of BMI-1 in the eight regions depicted by the black boxes. ChIP
was performed using a BMI-1 Ab and the line graph depicts the quantitation of the ChIP results by qPCR normalized to IgG. Data represent the average of two
separate experiments.
(J) Luciferase reporter constructs containing regions 1 and 2 of the ERb promoter (left graph) or region 1 (right graph) were expressed in PC3-M cells. Luciferase
activity was normalized to Renilla (±SEM) and the experiment was repeated three times with similar results. See also Figure S1.
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2013). Of particular relevance, we reported that autocrine VEGF
signaling results in the enhancement of BMI-1 expression by a
mechanism that involves Neuropilin-2 (NRP2) and Gli-1 (Goel
et al., 2012). Together, these observations support the hypothe-
sis that ERb repression is important for prostate tumorigenesis
induced by PTEN loss because it enables autocrine VEGF
signaling via HIF-1a stabilization that sustains BMI-1 expression.
Initially, we assessed HIF-1a and VEGF expression in wild-type
and Pten pc/ prostates. Deletion of PTEN induced the expres-
sion of HIF-1a, VEGF, as well as BMI-1 (Figures 3A–3C), in tumor
cells. This observation is supported by the analysis of PTEN-
depleted PNT1a cells, which express high levels of HIF-1a,
VEGF-A, and BMI-1 compared to control cells (shGFP) (Fig-
ure 3D). To demonstrate that the increase in VEGF and BMI-1
expression observed in response to PTEN deletion is dependent
on ERb repression, we expressed ERb in PTEN-depleted PNT1a
cells and observed a reduction in VEGF and BMI-1 expression
compared to controls (Figure 3E).
The results reported so far indicate that PTEN loss results in
the BMI-1-mediated repression of ERb and that repression of
ERb enables VEGF signaling that sustains BMI-1 expression. In
essence, the data reveal a positive feedback loop that functions
to maintain BMI-1 expression and is activated in response to
PTEN loss. This hypothesis infers that loss of ERb should induce
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Figure 3. Role of ERb Repression in Prostate Tumorigenesis
(A–C) Ventral prostates of wild-type (control) and aged-matched Pten pc/mice were stained for (A) HIF-1a, (B) VEGF-A, and (C) BMI-1 and analyzed by
immunofluorescence microscopy. Scale bar, 50 mm.
(D) Immunoblot shows the expression of HIF1a, VEGF-A, and BMI-1 in PTEN-depleted (shPTEN) and control (shGFP) PNT1a cells.
(E) Expression of VEGF-A and BMI-1 in ERb-expressing PTEN-depleted cells (shPTEN-2 + HA-ERb) was compared to PTEN-depleted cells (shPTEN).
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BMI-1 expression by a mechanism that involves HIF-1/VEGF
signaling. Indeed, depletion of ERb in PNT1a cells induced
HIF-1a, VEGF-A, and BMI-1 expression compared to the con-
trols (Figure 4A). We also observed an induction of NRP2 in
ERb-depleted cells with a concomitant increase in BMI-1 (Fig-
ure S2). Similar results were obtained by depleting PHD2, which
is sustained by ERb (Mak et al., 2013; Figure 4B). The PHD2-
depleted cells also had high expression levels of N-cadherin
and vimentin compared to the control cells, supporting our pre-
vious observation that loss of PHD2 induced an EMT in PNT1a
cells (Mak et al., 2013). To establish a causal role for HIF-1a in
regulating BMI-1 expression, we knocked down HIF-1a in ERb--
depleted cells and observed a substantial decrease in VEGF-A
and BMI-1 expression compared to ERb-depleted cells alone
(Figure 4C). These expression differences also were manifested
in cell morphology. Control (shGFP) and shERb/shHIF-1a cells
exhibited an epithelial morphology compared to the mesen-
chymal morphology of shERb/shGFP cells (Figure 4C). Based
on these data, the possibility existed that BMI-1 is a HIF-1a
target gene. However, promoter activity analyses did not sup-
port this possibility (data not shown). For this reason, we focused
on the role of VEGF-A signaling in regulating BMI-1 in the context
of ERb. Specifically, knocking down VEGF-A in ERb-depleted
cells attenuated BMI-1 expression and induced an epithelial
morphology (Figure 4D).
Subsequently, we analyzed the prostates of BERKO mice to
assess the impact of ERb loss on HIF-1a, VEGF, and BMI-1
expression. Ventral prostates of wild-type mice (control) ex-
hibited normal glandular structure with ERb expression in
epithelial cells and undetectable HIF-1a and BMI-1 and very
low VEGF-A expression (Figure 4E). In contrast, BERKO mice
of the same age and genetic background exhibited hyperplasia
and decreased epithelial differentiation with high HIF-1a,
VEGF-A, and BMI-1 expression in the absence of ERb (Fig-
ure 4E). Interestingly, both control and BERKO prostates
exhibited a similar intensity of PTEN staining (Figure 4E). Five
BERKO mice and their control counterparts were examined
with similar findings. These observations were substantiated
by the observation that a negative correlation between ERb
and BMI-1 expression exists in a cohort of 87 human prostate
tumors, based on analysis of the cBioportal database (Figures
4F; Table S2).
DISCUSSION
This study provides insight into the role of ERb in prostate tumor-
igenesis and the mechanisms that regulate its expression. First
and foremost, we demonstrate that prostate tumorigenesis
caused by PTEN deletion involves BMI-1-mediated repression
of ERb and that repression of ERb enables HIF-1/VEGF signaling
that sustains BMI-1 expression. These findings should help to
clarify the issue of why prostate cancer has not been observed
in BERKOmice. Specifically, we argue that loss of ERb is not suf-
ficient to promote tumorigenesis in the absence of an oncogenic
stimulus, despite the fact that BMI-1 expression is increased.
This hypothesis is consistent with the report that BMI-1 inhibition
slows the growth of PTEN-deletion-induced prostate cancer, but
it does not prevent tumorigenesis (Lukacs et al., 2010). In fact,
we found that BERKO prostates retain PTEN expression. A
reasonable hypothesis going forward is that PTEN loss involves
additional events, such as the enhancement of PI3K/Akt
signaling, that are essential for tumorigenesis (Worby and Dixon,
2014).
The fact that ERb expression is lost during tumorigenesis
caused by PTEN deletion is significant and relevant to other
studies that have investigated the consequences of ERb loss in
the prostate. Specifically, it was reported recently that deletion
of ERb in the FGF8b transgenic model of prostate tumorigenesis
did not increase tumor incidence (Elo et al., 2014). Although the
authors discounted a tumor-suppressive role for ERb based on
these data, this conclusion should be tempered by the likely pos-
sibility that FGF8b-mediated tumorigenesis involves repression
of ERb, similar to our finding with prostate tumorigenesis caused
by PTEN deletion. For this reason, deleting ERb in either the
FGF8b or PTEN models would not be expected to increase
tumor incidence.
This study also addresses the mechanism by which ERb is
regulated in prostate cancer. Several studies have observed
an inverse correlation between ERb expression and differentia-
tion (Gleason grade), but the mechanisms that contribute to the
loss of ERb in high-grade cancers are not well understood.
Some reports indicated that hypermethylation of the ERb pro-
moter is associated with loss of expression (Lau et al., 2000;
Zhu et al., 2004). Although our data do not discount the contri-
bution of promoter methylation, compelling evidence now ex-
ists that BMI-1 expression correlates with Gleason grade and
that BMI-1 is induced as a direct consequence of PTEN loss
or inactivation (Goel et al., 2012). Moreover, we detected an in-
verse correlation between ERb and BMI-1 in a cohort of human
prostate tumors. These observations, coupled with our demon-
stration that BMI-1 can bind to the ERb 0N promoter and
repress transcription, strongly implicate BMI-1 in the repression
of ERb in prostate cancer. Paradoxically, ERb is expressed in
prostate cancer metastases (Fixemer et al., 2003; Lai et al.,
2004). It is tempting to speculate that this ERb expression is
regulated by the 0K promoter, which is not repressed by
BMI-1. From a different perspective, these findings add a
new dimension to our understanding of how BMI-1 contributes
to prostate tumorigenesis. Although BMI-1 also has been
reported to suppress PTEN expression in nasopharyngeal
epithelial cells (Song et al., 2009), we did not observe this phe-
nomenon in the prostate epithelial and carcinoma cells that we
analyzed.
Our finding that ERb functions to suppress BMI-1 is significant
because it forms the basis of our hypothesis that a positive feed-
back loop exists that maintains BMI-1 expression. Although ERb
has been implicated as a gatekeeper that impedes prostate
tumorigenesis (Dey et al., 2013; Hussain et al., 2012; Slusarz
et al., 2012), the mechanisms involved are not known. Clearly,
its ability to repress BMI-1 is one such mechanism. Moreover,
these findings add to our understanding of how BMI-1 is regu-
lated in prostate cancer. Previous work by our group demon-
strated that autocrine VEGF signaling in tumor cells sustains
BMI-1 expression (Goel et al., 2012), but it was not apparent
that this pathway is subject to inhibition by ERb. As mentioned,
autocrine VEGF signaling in tumor cells is emerging as an
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Figure 4. ERb Represses BMI-1 by an HIF-1a/VEGF-Mediated Mechanism
(A) Expression of HIF-1a, VEGF-A, and BMI-1 in ERb-depleted PNT1a cells (shERb-1 and shERb-2) and control cells (shGFP) was assessed by immunoblotting.
(B) Expression of N-cadherin, vimentin, HIF-1a, VEGF-A, and BMI-1 in PHD2-depleted cells (shPHD2-1 and shPHD2-2) compared to control cells (shGFP) was
assessed by immunoblotting.
(C) HIF-1a expression was diminished in ERb-depleted PNT1a cells using shRNA, and the impact on cell morphology and expression of HIF-1a, VEGF-A, and
BMI-1 was determined. Scale bar, 50 mm.
(D) VEGF-A expression was diminished in ERb-depleted PNT1a cells using shRNA, and the impact on cell morphology (phase contrast images) and expression of
VEGF and BMI-1 was determined by immunoblotting.
(E) H&E staining of ventral prostates from 10-month-old wild-type (control) and BERKOmice. Arrows indicate areas of hyperplasia. These tissues were stained for
ERb, HIF-1a, VEGF-A, BMI-1, and PTEN and analyzed by immunofluorescence microscopy. Scale bar, 50 mm.
(F) An inverse correlation between BMI-1 and ERb in a cohort of 87 prostate tumors was determined from analysis of the cBioportal database (Figure S1B; Taylor
et al., 2010).
(G) Schematic summares the major conclusions of the study. See also Figure S2 and Table S2.
1988 Cell Reports 10, 1982–1991, March 31, 2015 ª2015 The Authors
important mechanism that sustains the function of cancer stem
cells and promotes tumor initiation, as evidenced by data ob-
tained from several different cancers including prostate (Goel
and Mercurio, 2013). Moreover, the ability of VEGF signaling to
sustain BMI-1 expression accounts for how this pathway con-
tributes to de-differentiation and tumorigenesis. The ability of
ERb to promote HIF-1a degradation and, consequently, repress
VEGF expression and signaling provides a mechanism for sup-
pressing the tumorigenic potential of BMI-1. Indeed, the induc-
tion of HIF-1a, VEGF, and BMI-1 expression in BERKO mice, in
concert with the inverse correlation observed between ERb
and these molecules in human prostate tumors, provides sup-
port for this hypothesis. These findings also reinforce the hypoth-
esis that loss of ERb in prostate cancer mimics hypoxia by
enabling HIF-1a/VEGF signaling. Interestingly, a tumor-suppres-
sive function for ERb in breast cancer was reported recently
(Yuan et al., 2014).
In summary, the data we report advance our understanding of
how ERb functions in prostate cancer as both a gatekeeper of
epithelial differentiation and tumorigenesis and a target of onco-
genic stimuli, as depicted in Figure 4G.
EXPERIMENTAL PROCEDURES
Cells and Reagents
PNT1a cells were obtained fromM. Littmann (Baylor College of Medicine). The
human prostate cancer cell line LNCaP was obtained from American Type
Culture Collection (ATCC). PC3-M cells were obtained from R.C. Bergan
(Northwestern University). 3b-androstane-diol (3b-adiol) and 17b-estradiol
(E2) experiments were performed by incubating cells with 3b-adiol (5 mM;
Sigma-Aldrich) or E2 (10 nM; Sigma-Aldrich) for 2 to 3 days. Wortmannin and
Akt inhibitor VIII were obtained from Calbiochem. Cells were incubated with
these inhibitors (5 mM) for 1820 hr prior to subsequent analyses. The
generation of ERb and PHD2-ablated PNT1a cells using small hairpin RNAs
(shRNAs) has been described previously (Mak et al., 2013). Lentiviruses
(pLKO.1) containing BMI-1 shRNA oligonucleotides (TRCN0000020154,
TRCN0000020156, and TRCN0000012565), VEGF-A shRNA oligonucleotides
(TRCN0000003343), HIF-1a shRNA (TRCN0000054449), PTEN shRNA
(TRCN0000028989 and TRCN0000028990), or pLKO-shGFP control were
purchased from Open Biosystems and used to infect cells following standard
protocols. Stable cell transfectants were generated by puromycin or
hygromycin selection (0.5 mg/ml for PNT1a and 2 mg/ml for PC3-M cells). The
resultant ERb-, PHD2-, BMI-1-, HIF-1a-, or VEGF-A-ablated cells were used
for subsequent experiments. A lentiviral plasmid (FUGW) expressing BMI-1
and the control vector (FUGW) carrying the empty vector (EV) were obtained
from Addgene.
Biochemical Analyses
For immunoblotting, the following Abs were used: ERb and PTEN (GeneTex),
BMI-1 (Cell Signaling Technology), vimentin (Dako), HIF-1a (Novus Biologi-
cals), PHD2 (Abcam), and a-tubulin and b-actin (Sigma-Aldrich). Immune com-
plexes were detected using enhanced chemiluminescence (ECL) (Pierce). For
quantitative real-time RT-PCR (qPCR), total RNA was extracted from cells us-
ing the TRI reagent (Sigma-Aldrich) and was reverse transcribed using reverse
transcription reagents (Applied Biosystems), and then analyzed by SYBR
Green Master (Rox) (Roche) using a real-time PCR system (ABI PRISM
7900HT Sequence Detection System, PE Biosystems). The expression of
target genes was normalized to 18 s RNA and analyzed by the comparative
cycle threshold method (DDCt).
ChIP was performed using the ChIP-IT Express kit (53008, Active Motif).
Briefly, the attached cells were cross-linked using 1% formaldehyde for
15 min at room temperature (RT) with rotation. Subsequent steps for ChIP
analysis were performed according to the manufacturer’s protocol. For chro-
matin precipitation, 3 mg BMI-1 antibody (Cell Signaling Technology) or human
isotype IgG (16-4301-81, eBioscience) was used. End-point real-time PCR
was performed using the primer pairs listed in Figure S1E. For luciferase as-
says, PC3-M cells were transfected with the desired plasmids and the Renilla
luciferase construct to normalize for transfection efficiency. Luciferase assays
were performed using Dual Glo luciferase assay system (Promega). Relative
luciferase activity was calculated as the ratio of firefly luciferase to Renilla
luciferase activity.
Xenograft Experiments
Cells were mixed with Matrigel (30%) and injected subcutaneously into nu/nu
mice (6 weeks old, Jackson ImmunoResearch Laboratories) using a single
dose as follows: PNT1a (106) and PC3-M (105). Animals were monitored three
times per week for tumor formation by palpation. All animal experiments were
in accordance with institutional guidelines and were approved by the Institu-
tional Animal Care and Use Committee at the University of Massachusetts
Medical School.
Transgenic Mice
ERb knockout (BERKO) mice were generated by the Korach laboratory (Krege
et al., 1998) and were purchased from The Jackson Laboratory. The knockout
allele was maintained on a C57BL/6 background. The mice used in these
studies were 10 months old. Sections from these prostates and age-matched
controls were processed for immunostaining as described below. A similar
approach was used for specimens obtained from prostate tissue obtained
from Ptenloxp/loxp; PB-Cre+ mice (prostate cancer) and age-matched Pten+/+;
PB-Cre+ mice (normal prostate) (Hu¨bner et al., 2012).
Immunostaining
Murine prostate specimens from transgenic mice (see above) and human
prostate cancer specimens, which were obtained from the Tissue Bank at
the University of Massachusetts Medical School, were fixed in paraformalde-
hyde (4%), embedded in paraffin, sectioned (5 mM), and used for H&E and
immunofluorescence staining. Immunofluorescence staining was conducted
according to themanufacturer’s instructions (Invitrogen and Life Sciences). Af-
ter antigen unmasking, the specimens were incubated in 10% serum in PBS
for 30 min, washed for 3 min in PBST, and incubated with rabbit polyclonal
ERb antibody (GTX 112927, GeneTex) or rabbit BMI-1 mAb (5856S, Cell
Signaling Technology) overnight at 4C. The slides were washed 5 min with
PBST and incubated 45 min in a dark chamber with the fluorochrome-conju-
gated secondary antibody (goat anti-rabbit conjugated Alexa Fluor 488,
A-11008, Life Sciences). Slides were washed and counterstained in the dark
with DAPI (Invitrogen) for 10 min, washed with three changes of PBST, and
mounted under coverslips with aqueous mounting medium (Thermo Electron).
Results were analyzed with an LSM 710 Meta confocal microscope (Carl
Zeiss).
Statistical Analysis
Data are presented as the mean from three separate experiments ± SD. The
Student’s t test was used to determine the significance of independent exper-
iments. The criterion p < 0.05 was used to determine statistical significance.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables and two figures and can be
foundwith this article online at http://dx.doi.org/10.1016/j.celrep.2015.02.063.
AUTHOR CONTRIBUTIONS
P.M. designed, executed, and analyzed all experiments and wrote the manu-
script. J.L. designed, executed, and analyzed experiments. S.S. performed the
ChIP experiments. C.C. performed the database analyses andmolecular clon-
ing. D.J.J. provided the ERb knockout mice. R.J.D. provided the PTENpc/
mice. I.L. evaluated the pathology of all tissue specimens and contributed to
the overall focus of the study. A.M.M. supervised the study and wrote the
manuscript together with P.M.
Cell Reports 10, 1982–1991, March 31, 2015 ª2015 The Authors 1989
ACKNOWLEDGMENTS
NIH grant CA159865 supported this work.
Received: November 19, 2014
Revised: February 3, 2015
Accepted: February 24, 2015
Published: March 26, 2015
REFERENCES
Antal, M.C., Krust, A., Chambon, P., andMark, M. (2008). Sterility and absence
of histopathological defects in nonreproductive organs of amouse ERbeta-null
mutant. Proc. Natl. Acad. Sci. USA 105, 2433–2438.
Berthon, P., Cussenot, O., Hopwood, L., Leduc, A., and Maitland, N. (1995).
Functional expression of sv40 in normal human prostatic epithelial and fibro-
blastic cells - differentiation pattern of nontumorigenic cell-lines. Int. J. Oncol.
6, 333–343.
Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J.G.,
Jen, J., Isaacs, W.B., Bova, G.S., and Sidransky, D. (1997). Frequent inactiva-
tion of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57, 4997–5000.
Cao, R., Tsukada, Y., and Zhang, Y. (2005). Role of Bmi-1 and Ring1A in H2A
ubiquitylation and Hox gene silencing. Mol. Cell 20, 845–854.
Christoforou, P., Christopoulos, P.F., and Koutsilieris, M. (2014). The role of
estrogen receptor b in prostate cancer. Mol. Med. 20, 427–434.
Dey, P., Barros, R.P., Warner, M., Stro¨m, A., and Gustafsson, J.A. (2013).
Insight into the mechanisms of action of estrogen receptor b in the breast,
prostate, colon, and CNS. J. Mol. Endocrinol. 51, T61–T74.
Elo, T., Yu, L., Valve, E., Ma¨kela¨, S., and Ha¨rko¨nen, P. (2014). Deficiency of ERb
and prostate tumorigenesis in FGF8b transgenic mice. Endocr. Relat. Cancer
21, 677–690.
Fixemer, T., Remberger, K., and Bonkhoff, H. (2003). Differential expression of
the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant
changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma.
Prostate 54, 79–87.
Goel, H.L., and Mercurio, A.M. (2013). VEGF targets the tumour cell. Nat. Rev.
Cancer 13, 871–882.
Goel, H.L., Chang, C., Pursell, B., Leav, I., Lyle, S., Xi, H.S., Hsieh, C.C., Adi-
setiyo, H., Roy-Burman, P., Coleman, I.M., et al. (2012). VEGF/neuropilin-2
regulation of Bmi-1 and consequent repression of IGF-IR define a novel mech-
anism of aggressive prostate cancer. Cancer Discov. 2, 906–921.
Hirata, S., Shoda, T., Kato, J., and Hoshi, K. (2001). The multiple untranslated
first exons system of the human estrogen receptor beta (ER beta) gene.
J. Steroid Biochem. Mol. Biol. 78, 33–40.
Hu¨bner, A., Mulholland, D.J., Standen, C.L., Karasarides, M., Cavanagh-
Kyros, J., Barrett, T., Chi, H., Greiner, D.L., Tournier, C., Sawyers, C.L., et al.
(2012). JNK and PTEN cooperatively control the development of invasive
adenocarcinoma of the prostate. Proc. Natl. Acad. Sci. USA 109, 12046–
12051.
Hussain, S., Lawrence, M.G., Taylor, R.A., Lo, C.Y., Frydenberg, M., Ellem,
S.J., Furic, L., and Risbridger, G.P.; APC BioResource (2012). Estrogen recep-
tor b activation impairs prostatic regeneration by inducing apoptosis in murine
and human stem/progenitor enriched cell populations. PLoS ONE 7, e40732.
Imamov, O., Morani, A., Shim, G.J., Omoto, Y., Thulin-Andersson, C., Warner,
M., and Gustafsson, J.A. (2004). Estrogen receptor beta regulates epithelial
cellular differentiation in the mouse ventral prostate. Proc. Natl. Acad. Sci.
USA 101, 9375–9380.
Jacobs, J.J., Kieboom, K., Marino, S., DePinho, R.A., and van Lohuizen, M.
(1999). The oncogene and Polycomb-group gene bmi-1 regulates cell prolifer-
ation and senescence through the ink4a locus. Nature 397, 164–168.
Kozlowski, J.M., Fidler, I.J., Campbell, D., Xu, Z.L., Kaighn, M.E., and Hart, I.R.
(1984). Metastatic behavior of human tumor cell lines grown in the nude
mouse. Cancer Res. 44, 3522–3529.
Krege, J.H., Hodgin, J.B., Couse, J.F., Enmark, E., Warner, M., Mahler, J.F.,
Sar, M., Korach, K.S., Gustafsson, J.A., and Smithies, O. (1998). Generation
and reproductive phenotypes of mice lacking estrogen receptor beta. Proc.
Natl. Acad. Sci. USA 95, 15677–15682.
Kuiper, G.G., Enmark, E., Pelto-Huikko, M., Nilsson, S., and Gustafsson, J.A.
(1996). Cloning of a novel receptor expressed in rat prostate and ovary. Proc.
Natl. Acad. Sci. USA 93, 5925–5930.
Lai, J.S., Brown, L.G., True, L.D., Hawley, S.J., Etzioni, R.B., Higano, C.S., Ho,
S.M., Vessella, R.L., and Corey, E. (2004). Metastases of prostate cancer
express estrogen receptor-beta. Urology 64, 814–820.
Lau, K.M., LaSpina, M., Long, J., and Ho, S.M. (2000). Expression of estrogen
receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial
cells: regulation by methylation and involvement in growth regulation. Cancer
Res. 60, 3175–3182.
Leav, I., Lau, K.M., Adams, J.Y., McNeal, J.E., Taplin, M.E., Wang, J., Singh,
H., and Ho, S.M. (2001). Comparative studies of the estrogen receptors beta
and alpha and the androgen receptor in normal human prostate glands,
dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159,
79–92.
Lukacs, R.U., Memarzadeh, S., Wu, H., and Witte, O.N. (2010). Bmi-1 is a
crucial regulator of prostate stem cell self-renewal and malignant transforma-
tion. Cell Stem Cell 7, 682–693.
Mak, P., Leav, I., Pursell, B., Bae, D., Yang, X., Taglienti, C.A., Gouvin, L.M.,
Sharma, V.M., and Mercurio, A.M. (2010). ERbeta impedes prostate cancer
EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear
localization: implications for Gleason grading. Cancer Cell 17, 319–332.
Mak, P., Chang, C., Pursell, B., andMercurio, A.M. (2013). Estrogen receptor b
sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcrip-
tion. Proc. Natl. Acad. Sci. USA 110, 4708–4713.
McMenamin, M.E., Soung, P., Perera, S., Kaplan, I., Loda, M., and Sellers,
W.R. (1999). Loss of PTEN expression in paraffin-embedded primary prostate
cancer correlates with high Gleason score and advanced stage. Cancer Res.
59, 4291–4296.
Miyazaki, M., Miyazaki, K., Itoi, M., Katoh, Y., Guo, Y., Kanno, R., Katoh-Fukui,
Y., Honda, H., Amagai, T., van Lohuizen, M., et al. (2008). Thymocyte prolifer-
ation induced by pre-T cell receptor signaling is maintained through polycomb
gene product Bmi-1-mediated Cdkn2a repression. Immunity 28, 231–245.
Mulholland, D.J., Kobayashi, N., Ruscetti, M., Zhi, A., Tran, L.M., Huang, J.,
Gleave, M., and Wu, H. (2012). Pten loss and RAS/MAPK activation cooperate
to promote EMT and metastasis initiated from prostate cancer stem/progeni-
tor cells. Cancer Res. 72, 1878–1889.
Nacerddine, K., Beaudry, J.B., Ginjala, V., Westerman, B., Mattiroli, F., Song,
J.Y., van der Poel, H., Ponz, O.B., Pritchard, C., Cornelissen-Steijger, P., et al.
(2012). Akt-mediated phosphorylation of Bmi1modulates its oncogenic poten-
tial, E3 ligase activity, and DNA damage repair activity in mouse prostate
cancer. J. Clin. Invest. 122, 1920–1932.
Slusarz, A., Jackson, G.A., Day, J.K., Shenouda, N.S., Bogener, J.L., Brown-
ing, J.D., Fritsche, K.L., MacDonald, R.S., Besch-Williford, C.L., and Lubahn,
D.B. (2012). Aggressive prostate cancer is prevented in ERaKO mice and
stimulated in ERbKO TRAMP mice. Endocrinology 153, 4160–4170.
Song, L.B., Li, J., Liao, W.T., Feng, Y., Yu, C.P., Hu, L.J., Kong, Q.L., Xu, L.H.,
Zhang, X., Liu,W.L., et al. (2009). The polycomb group protein Bmi-1 represses
the tumor suppressor PTEN and induces epithelial-mesenchymal transition in
human nasopharyngeal epithelial cells. J. Clin. Invest. 119, 3626–3636.
Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S.,
Arora, V.K., Kaushik, P., Cerami, E., Reva, B., et al. (2010). Integrative genomic
profiling of human prostate cancer. Cancer Cell 18, 11–22.
Thomas, C., and Gustafsson, J.A. (2011). The different roles of ER subtypes in
cancer biology and therapy. Nat. Rev. Cancer 11, 597–608.
van Leenders, G.J., Dukers, D., Hessels, D., van den Kieboom, S.W., Hulsber-
gen, C.A., Witjes, J.A., Otte, A.P., Meijer, C.J., and Raaphorst, F.M. (2007).
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in
1990 Cell Reports 10, 1982–1991, March 31, 2015 ª2015 The Authors
prostate cancer with adverse pathologic and clinical features. Eur. Urol. 52,
455–463.
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G.V.,
Li, G., Roy-Burman, P., Nelson, P.S., et al. (2003). Prostate-specific deletion of
the murine Pten tumor suppressor gene leads to metastatic prostate cancer.
Cancer Cell 4, 209–221.
Worby, C.A., and Dixon, J.E. (2014). Pten. Annu. Rev. Biochem. 83, 641–669.
Yuan, B., Cheng, L., Chiang, H.C., Xu, X., Han, Y., Su, H., Wang, L., Zhang, B.,
Lin, J., Li, X., et al. (2014). A phosphotyrosine switch determines the antitumor
activity of ERb. J. Clin. Invest. 124, 3378–3390.
Zhu, X., Leav, I., Leung, Y.K., Wu, M., Liu, Q., Gao, Y., McNeal, J.E., and Ho,
S.M. (2004). Dynamic regulation of estrogen receptor-beta expression by DNA
methylation during prostate cancer development and metastasis. Am. J.
Pathol. 164, 2003–2012.
Cell Reports 10, 1982–1991, March 31, 2015 ª2015 The Authors 1991
